Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sugar boost: when ribose modifications improve oligonucleotide performance.

Marcella Faria1, Henning Ulrich

  • 1Instituto Butantan, Laboratório Especial de Toxinologia Aplicada CAT-CEPID, São Paulo, Brazil.

Current Opinion in Molecular Therapeutics
|April 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Purinergic-cytokine signaling as a regulatory axis in neuroimmune development.

Neuropharmacology·2026
Same author

The Flavonoid Rutin Enhances Temozolomide Sensitivity in Glioblastoma Spheroids by Modulating Chemoresistance via PI3K/AKT, STAT3, Redox and Kynurenine Pathways, and Altering ECM Remodeling Associated with Reduced Migration.

Antioxidants (Basel, Switzerland)·2026
Same author

Uncovering Spatiotemporal and Functional Dynamics of Long Non-coding RNAs During Alzheimer's Progression in the Human Brain at Single-Cell Resolution.

Molecular neurobiology·2026
Same author

Methodological guidelines for P2X receptor assays and data interpretation.

Cell death & disease·2026
Same author

GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

In tribute to Francesco Di Virgilio, a great scientist and a wonderful friend.

Purinergic signalling·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Synthetic oligonucleotides are crucial for gene expression modulation. Chemical modifications enhance their therapeutic performance, improving nuclease resistance and activity, though predicting combined effects remains challenging.

Area of Science:

  • Biochemistry and Molecular Biology
  • Medicinal Chemistry
  • Therapeutic Oligonucleotide Development

Background:

  • Synthetic oligonucleotides have been utilized for gene expression modulation for over 30 years in research and therapeutics.
  • Chemical modifications are essential for enhancing the performance of oligonucleotides in therapeutic applications.

Purpose of the Study:

  • To review chemical modifications applied to various oligonucleotide therapeutics, including antisense, aptamer, and short interfering RNA (siRNA).
  • To discuss strategies for improving oligonucleotide activity and nuclease resistance.
  • To evaluate the potential of mixed oligonucleotides through systematic approaches.

Main Methods:

  • Review of literature on chemical modifications of nucleotides.

Related Experiment Videos

  • Analysis of backbone substitutions (e.g., phosphorothioates, 4'-thio RNA analogs) for nuclease resistance.
  • Examination of 2'-O-modifications on the ribose sugar for improved activity.
  • Discussion of systematic approaches to evaluate mixed oligonucleotides.

    • Main Results:

    • Backbone modifications like phosphorothioates and 4'-thio RNA analogs enhance resistance to nuclease degradation.
    • 2'-O-modifications of the ribose sugar can improve oligonucleotide activity.
    • Crystallization studies support increased thermodynamic stability with 2'-O-modifications.
    • No simple predictive rules exist for the combined effects of individual modifications in mixed oligonucleotides.

    Conclusions:

    • Chemical modifications are vital for advancing oligonucleotide therapeutics, offering improved stability and activity.
    • While specific modifications show benefits, rational design of mixed oligonucleotides requires further investigation due to complex interactions.
    • Continued research into oligonucleotide chemistry is necessary for optimizing therapeutic applications.